Genetic Technologies Limited (NASDAQ:GENE) shares were up 5.4% on Friday . The stock traded as high as $0.62 and last traded at $0.59, approximately 135,387 shares were traded during mid-day trading. A decline of 72% from the average daily volume of 480,932 shares. The stock had previously closed at $0.56.
Separately, ValuEngine cut shares of Genetic Technologies from a “buy” rating to a “hold” rating in a research note on Monday, May 13th.
The company’s 50 day simple moving average is $0.63.
About Genetic Technologies (NASDAQ:GENE)
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Further Reading: What does a market perform rating mean?
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.